11 December 2013 - Chief Executive Steffan Crausaz says the price being asked by Alexion is $670,000 per patient per year, making it one of the most expensive drugs PHARMAC has ever assessed.

“It’s one of the most expensive medicines we’ve evaluated; but it’s not the most effective and that’s the core of the problem,” says Steffan Crausaz.“

The price Alexion is offering is higher than is charged overseas, and higher than the cost charged by competitors for similar drugs for other rare conditions, one of which we have just funded for another rare blood disorder.”

For more details, go to: http://www.pharmac.health.nz/news/item/media-eculizumab-funding-declined